Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit alleges that MoonLake and its executives misrepresented the clinical advantages of SLK, which was claimed to have a unique Nanobody structure [8] - It is claimed that SLK targeted the same molecules as UCB's BIMZELX, contradicting the company's assertions of superiority [8] - The stock price fell 89.9% on September 29, 2025, after the announcement of the Phase 3 trial results [8] Next Steps - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [8]

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for allegedly making misleading statements regarding its initiatives and projects during the class period from July 23, 2025, to October 29, 2025, leading to investor losses [7]. Group 1: Allegations - The lawsuit claims that Fiserv made false and misleading statements about its 2025 guidance, which was revised in July 2025 based on a review of new initiatives and products [7]. - Fiserv indicated that while some initiatives were delayed, they were fundamentally sound, which was later revealed to be untrue [7]. - The company admitted in October 2025 that the guidance provided in July was based on assumptions that were difficult to achieve, leading to artificially inflated security prices [7]. Group 2: Legal Process - Investors who purchased Fiserv securities during the class period have until January 5, 2026, to apply to be appointed as lead plaintiff in the lawsuit [7]. - The law firm Bragar Eagel & Squire, P.C. is representing the investors and encourages those affected to contact them for more information [4][5].

Core Points - A class action lawsuit has been filed against Cepton, Inc. in the United States District Court for the Northern District of California on behalf of investors who purchased Cepton common stock between July 29, 2024, and January 6, 2025 [6] - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations, including failing to disclose a credible third-party bid that valued Cepton at more than double the Koito Acquisition [2] Allegation Details - The complaint claims that Cepton's Board of Directors did not adequately explore a third-party bid and failed to disclose its terms when recommending the Koito Acquisition to shareholders [2] - As a result, shareholders were deprived of the opportunity to meaningfully consider the acquisition, leading to materially false and misleading public statements by the defendants [2] Next Steps - Investors who acquired Cepton shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [3] - There is a deadline of December 8, 2025, for investors to apply to be appointed as lead plaintiff in the lawsuit [6]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, stating it would occur in the second half of 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [8]. - On May 6, 2025, it was revealed during an earnings call that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [8]. Next Steps - Investors who purchased Cytokinetics shares between December 27, 2023, and May 6, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 17, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against Telix Pharmaceuticals Limited regarding possible violations of federal securities laws and unlawful business practices [1][2] - The investigation is aimed at stockholders who have suffered losses from their investments in Telix [1][2] - Telix's stock price experienced a significant decline following the announcement of a subpoena from the U.S. Securities and Exchange Commission, which sought documents related to the company's prostate cancer therapeutic candidates [5] Investigation Details - Investors who purchased Telix shares and incurred losses are encouraged to contact Bragar Eagel & Squire for more information about their legal rights and potential claims [2] - The law firm emphasizes that there is no cost or obligation for investors to inquire about their rights [2] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, specializing in representing individual and institutional investors in complex litigation [3] - The firm handles cases in both state and federal courts across the country [3]

Core Insights - A class action lawsuit has been filed against James Hardie Industries plc for allegedly making false statements regarding the demand for its North America Fiber Cement segment, which was reportedly experiencing weakening demand due to distributor inventory destocking [3][7] - The lawsuit claims that James Hardie misrepresented the strength of demand and inventory levels, leading to a significant drop in share price of over 34% following the disclosure of a 12% sales decline in the segment [3][7] Allegation Details - The complaint alleges that James Hardie was aware of weakening demand in its key segment by April and May 2025 but failed to disclose this information [3] - The company falsely represented that demand remained strong and inventory levels were "normal" during the class period [3] - On August 19, 2025, James Hardie announced a 12% sales decline in the North America Fiber Cement segment, attributing it to "normalization of channel inventories" and warned of continued weakness [3] - Following this announcement, the company's share price dropped more than 34%, impacting investors significantly [3] Next Steps - Investors who purchased James Hardie shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information on their rights and potential claims [4][7] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 23, 2025 [7]

Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for allegedly misleading investors regarding its revenue outlook and sales performance during the class period from July 15, 2025, to August 14, 2025 [7]. Allegation Details - The lawsuit claims that Fly-E's management created a false impression of reliable information about the company's projected revenue and sales, while in reality, the company's optimistic goals fell short [7]. - The complaint highlights that Fly-E's revenue decreased by 32% compared to the same period in 2024, primarily due to a decline in total units sold, attributed to customer hesitance stemming from lithium battery explosion incidents [7]. - Following the SEC filing on August 14, 2025, which disclosed the revenue drop, Fly-E's stock price plummeted approximately 87%, from $7.76 per share to $1.00 per share within a day [7]. Next Steps - Investors who purchased Fly-E shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from November 30, 2023, to July 3, 2025 [3][8]. Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact the results of ongoing studies and the regulatory and commercial prospects of its products, particularly briquilimab [3]. - The failure to maintain proper controls increased the likelihood of disruptive cost-reduction measures and overstated the company's business and financial prospects [3]. Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified class period from February 18, 2025, to July 31, 2025 [3][7]. Allegation Details - The complaint claims that Fluor's management failed to disclose significant cost increases related to major projects, including the Gordie Howe, I-635/LBJ, and I-35 projects, due to subcontractor design errors, price hikes, and scheduling delays [3]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a substantial negative impact on Fluor's business and financial results [3]. - The financial guidance provided by Fluor for FY 2025 is described as unreliable and unrealistic, with an overstated effectiveness of the company's risk mitigation strategies [3]. Next Steps - Investors who purchased Fluor shares and experienced losses are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 14, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation (QMCO) for allegedly making false statements and failing to disclose improper revenue recognition, leading to the need for restating financial statements [3][7]. Allegation Details - The lawsuit claims that Quantum Corporation improperly recognized revenue during the fiscal year ended March 31, 2025 [3]. - As a result of this improper recognition, Quantum Corporation is required to restate its previously filed financial statements for the fiscal third quarter ended December 31, 2024 [3]. - The defendants' statements regarding the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis at all times [3]. Next Steps - Investors who purchased Quantum shares between November 15, 2024, and August 18, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - There is no cost or obligation for investors to inquire about their potential claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across state and federal courts [5].